Enhanced treatment of liver carcinoma with a drug-eluting hydrogel

More effective tumor cell death enabled via controlled, sustained delivery of chemo and immunotherapeutic drugs

2023-11-29

(Press-News.org) (LOS ANGELES) – November 29, 2023 - Scientists from the Terasaki Institute for Biomedical Innovation (TIBI) have developed an injectable or catheter-administered hydrogel with enhanced capabilities for treating hepatocellular carcinoma (HCC), a deadly form of liver cancer. As described in their recent publication in Advanced Functional Materials, this drug-eluting hydrogel can provide sustained, pH-dependent drug co-delivery and has capabilities for promoting anti-tumor immune responses. This reduces tumor cell proliferation and growth and offers a more efficient means of enabling tumor cell death.

Worldwide, HCC is a leading cause of cancer-related deaths, with an estimated one million new HCC cases to be diagnosed by 2025. Effective treatment options remain elusive. If diagnosed at an early stage, smaller liver tumors may be surgically removed, but tumor recurrence occurs in 70% of these patients. Liver transplantation also offers hope, but there is a huge shortage of suitable liver donors available, and successful outcomes are usually observed only in early diagnosis cases.

Another commonly used treatment method is trans-arterial chemoembolization, or TACE. In this technique, small microbead particles are delivered through a catheter into an artery that is supplying oxygen and nutrient-containing blood to a tumor. The particles block blood flow from the artery and thereby restrict tumor growth. Concurrently, the particles may serve as anti-cancer drug delivery vehicles which target the tumor cells; the restricted blood flow caused by the vessel blockage also serves to concentrate the drug around the tumor.

While offering a more targeted and safe approach than previous systemic chemotherapeutic approaches, the TACE method is not without inherent problems, with non-uniform bead dispersion occurring because the beads may break apart or aggregate; this limits their ability to penetrate deeply into tumors.

Also, the delivery of chemotherapeutic drugs to the tumor site may not be enough to destroy malignant tumor growth. These types of tumors exhibit unrestricted growth because they have found ways to suppress the body’s normal immune response system. Immunotherapeutic drugs can reverse this suppression and reinstate the body’s natural immune defenses to destroy tumor cells and inhibit their growth.

Given the known abilities of the chemotherapeutic agent, doxorubicin (DOX), to prime tumor cells for immunogenic cell death, the TIBI researchers sought to design a drug delivery system that could deliver both DOX and an immunotherapeutic drug, anti-PD-1, sequentially in a targeted, sustained and controllable manner. Using in vitro optimization experiments, the team formulated a Laponite®-containing gelatin hydrogel for this purpose. Laponite® nanoclay not only improves injectability but confers pH-controlled delivery as well.

In subsequent in vitro experiments, the team was able to identify the optimum formulation and pH conditions for both DOX and anti-PD-1 release by the hydrogel. They were also able to establish that DOX release by the hydrogel induced more effective priming of anti-tumor immune responses at the tumor site.

The efficacy of this drug delivery hydrogel platform was tested in in vivo experiments in which mouse liver tumor cells were injected into mouse models, followed by treatments with both dual (DOX+anti-PD1) and singly (DOX) loaded hydrogels. The mice were monitored for tumor size and survival time, and it was found that the subjects treated with combined DOX and anti-PD-1 loaded hydrogels had the longest survival times and smallest tumor size.

Other tests revealed that the combination drug loaded hydrogels also exhibited the greatest infiltration by anti-tumor immune cells, as well as the biggest reduction in tumor cell proliferation and the most increased level of tumor cell death.

“The one-two punch of combined chemotherapeutic and immunotherapeutic drug deliveries boosts the anti-tumor efficacy against hepatocellular carcinoma,” said TIBI’s Director and CEO, Ali Khademhosseini, PhD. “Our approach enhances current methods of treatment and offers renewed hope for patients with this deadly disease.”

Authors are Natashya Falcone, Menekse Ermis, Ankit Gangrade, Auveen Choroomi, Patric Young, Tess G. Mathes, Mahsa Monirizad, Fatemeh Zehtabi, Marvin Mecwan, Marco Rodriguez, Yangzhi Zhu, Youngjoo Byun, Ali Khademhosseini, Natan Roberto de Barros, and Han-Jun Kim.

The authors gratefully acknowledge funding from the National Institutes of Health (CA257558, DK130566). N.F. appreciates the postdoctoral fellowship (PDF) from the National Science and Engineering Research Council (NSERC). H-J.K. would like to acknowledge the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (RS-2023-00240729). This research was supported by the MSIT (Ministry of Science and ICT), Korea, under the ITRC (Information Technology Research Center) support program (IITP-2023-RS-2023-00258971) supervised by the IITP (Institute for Information & Communications Technology Planning & Evaluation). This research was also supported by a Korea University Grant (KU S-FRG; K2319831). This work was supported by the National Research Foundation (NRF) of Korea (2019R1A6A1A03031807).

PRESS CONTACT

Stewart Han, shan@terasaki.org, +1 818-836-4393

Terasaki Institute for Biomedical Innovation

###

About the Terasaki Institute for Biomedical Innovation

The Terasaki Institute for Biomedical Innovation is accelerating the pace of translational research by supporting the world’s leading scientists with an open, entrepreneurial environment for bioengineering new materials, biological models, and advanced technologies to address critical challenges to the health of the planet and its people. The Institute’s worldwide collaborations with academic, clinical, and entrepreneurial partners provide a rich foundation for translating innovations to the real world.

Contact:
Stewart Han
President
Terasaki Institute for Biomedical Innovation
shan@terasaki.org

END

[Attachments] See images for this press release:

Enhanced treatment of liver carcinoma with a drug-eluting hydrogel 2

Enhanced treatment of liver carcinoma with a drug-eluting hydrogel 3

ELSE PRESS RELEASES FROM THIS DATE:

Applying semiconductor manufacturing principles to optoelectronic devices

2023-11-29

Optoelectronics detect or emit light and are used in a variety of devices in many different industries. These devices have historically relied on thin transistors, which are small semiconductors that control the movement of electrons and photons, made out of graphene and other two-dimensional materials. However, graphene and these other materials often have problems with band gap opening and other shortcomings that have researchers searching for an alternative. When treated with a method called the ...

The role of marketing in disrupted health care markets: It’s time to move beyond conventional strategies to account for new actors, roles, and exchanges

2023-11-29

Researchers from Duke University, University of New South Wales, University of Wisconsin, and University of Washington published an editorial for the Journal of Marketing that calls for marketing to tackle the challenges and opportunities in dynamic contemporary health care markets. The editorial, introducing a special issue on “Marketing in the Health Care Sector” for the Journal of Marketing, is titled “Marketing in the Health Care Sector: Disrupted Exchanges and New Research Directions” and is authored by Christine Moorman, Harald J. van Heerde, C. Page Moreau, and Robert W. Palmatier. The special issue ...

Can we crack this cancer’s immune response?

2023-11-29

Recent findings at Cold Spring Harbor Laboratory (CSHL) shine a new light on pancreatic cancer. More than 90% of pancreatic cancer cases are attributed to an aggressive, deadly form of the disease called pancreatic ductal adenocarcinoma, or PDAC. Researchers have a poor understanding of how our immune system interacts with PDAC. So, coming up with treatments is tricky. It’s thought patients do not show a natural immune response to the cancer because the tumor environment somehow prevents that response. Many are unconvinced that PDAC ...

Building blocks for life could have formed near new stars and planets

2023-11-29

While life on Earth is relatively new, geologically speaking, the ingredients that combined to form it might be much older than once thought. According to research published in ACS Central Science, the simplest amino acid, carbamic acid, could have formed alongside stars or planets within interstellar ices. The findings could be used to train deep space instruments like the James Webb Space Telescope to search for prebiotic molecules in distant, star-forming regions of the universe. It has long been hypothesized that one of the building blocks for life, amino acids, could have formed during reactions in the “primordial ...

Uttam Superrhiza named as winner of Applied Microbiology International Product of the Year 2023

2023-11-29

Mycorrhiza biofertilizer Uttam Superrhiza has been named as the winner of the Applied Microbiology International Product of the Year 2023. The prestigious prize recognizes a commercial product derived from microbiology research, with special consideration given to those products that have addressed the United Nations Sustainable Development Goals. Uttam Superrhiza, marketed by Chambal Fertilizers and Chemicals Limited in India, is manufactured by the not-for-profit institute, The Energy and Resources Institute (TERI). Disruptive mycorrhiza A disruptive ...

Contactless Coupler, the innovation and advancement in the connection of precast concrete member

2023-11-29

The Korea Institute of Civil Engineering and Building Technology (KICT, President Kim, Byung-Suk) has developed a new Contactless Coupler that can efficiently improve the constructability of precast concrete (hereinafter referred to as PC). Recently, Off-site Construction (OSC) has been actively used worldwide to solve the problems at complex construction sites. The OSC method minimizes on-site work by prefabricating parts of the structure and then simply assembling and constructing them on-site. In particular, Korean construction sites are promoting OSC to solve the problem of aging skilled workers and labor shortages. The PC method, one of the representative OSC methods, is a method ...

Swapping blood for spit — for convenient at-home health monitoring

2023-11-29

Blood tests are a common, yet often painful, step in health care. But what if we could skip the needles altogether? Saliva and blood contain many of the same biomarkers, and collecting spit is as simple as drooling into a container. Researchers reporting in ACS Sensors have developed a device that detects glucose and adenosine monophosphate (AMP) biomarkers in saliva with high sensitivity, which could help make at-home health monitoring easier and without a poke. Blood tests provide critical information about a person’s health. But they also rely on uncomfortable procedures, ranging from collecting small blood samples through frequent finger pricks to blood draws from ...

Conscientious personalities less at risk of dementia diagnosis

2023-11-29

People with personality traits such as conscientiousness, extraversion and positive affect are less likely to be diagnosed with dementia than those with neuroticism and negative affect, according to a new analysis by researchers at the University of California, Davis and Northwestern University. The difference was not linked to physical damage to brain tissue found in dementia patients, but more likely to how certain personality traits help people navigate dementia-related impairments. The work is published Nov. ...

AI may aid in diagnosing adolescents with ADHD

2023-11-29

CHICAGO – Using artificial intelligence (AI) to analyze specialized brain MRI scans of adolescents with and without attention-deficit/hyperactivity disorder (ADHD), researchers found significant differences in nine brain white matter tracts in individuals with ADHD. Results of the study will be presented today at the annual meeting of the Radiological Society of North America (RSNA). ADHD is a common disorder often diagnosed in childhood and continuing into adulthood, according to the Centers for Disease Control and Prevention. In the U.S., an estimated 5.7 million children and adolescents between the ages of 6 and 17 have been diagnosed with ADHD. “ADHD often ...

Common headaches tied to neck inflammation

2023-11-29

CHICAGO – Researchers have identified objective evidence of how the neck muscles are involved in primary headaches, according to a study being presented today at the annual meeting of the Radiological Society of North America (RSNA). The findings could lead to better treatments. The distinct underlying causes of primary headaches are still not fully understood. The most common primary headaches are tension-type headaches and migraines. “Our imaging approach provides first objective evidence for the very frequent involvement of the neck muscles in primary headaches, such as neck pain ...

Enhanced treatment of liver carcinoma with a drug-eluting hydrogel

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: